Onconase cytotoxic pancreatic RNase data

ACEL presented interim results of an ongoing Phase II trial at the International Mesothelioma Conference in Philadelphia. A total of 63 patients received 480 µg/m2 Onconase weekly by IV, 26 of whom are still alive. Five patients withdrew due to adverse effects. For all patients, median survival times were 10.1 months from initiation of treatment (24.7 months from diagnosis), and time to disease progression was 13.3 months for 4 patients who achieved partial response versus 1.7 months for non-responders. ...